Patent Intelligence · Domain Comparison
PharmaceuticalsvsGene Editing
Side-by-side comparison across 8 patent dimensions: portfolio size, citation quality, concentration, prosecution speed, claim breadth, expiry opportunity, and filing velocity.
Pharmaceuticals
Patents
102
Citations
46,823
Avg citations
459.1
3yr CAGR
-20.6%
HHI
286
Expiring ≤2029
4.8%
Avg prosecution
43 mo
Avg claims
24.0
Gene Editing
Patents
11
Citations
19,679
Avg citations
1789.0
3yr CAGR
0.0%
HHI
1,074
Expiring ≤2029
0.0%
Avg prosecution
39 mo
Avg claims
33.7
Head-to-Head Comparison
| Metric | Pharmaceuticals | Gene Editing |
|---|---|---|
| Total patents | 102▲ | 11 |
| Total citations | 46,823▲ | 19,679 |
| Avg citations/patent | 459.1 | 1,789▲ |
| 3-year CAGR | -20.6% | 0.0%▲ |
| HHI concentration | 286▲ | 1,074 |
| Expiring ≤2029 | 4.8%▲ | 0.0% |
| Avg prosecution (mo) | 43 | 39▲ |
| Avg claims/patent | 24 | 33.7▲ |
▲ = higher is better for that metric. HHI: lower = more competitive landscape.
Grant Trend 2015–Present
Patents granted per year by domain.
2016
2018
2020
2022
Domain A
Domain B
Other comparisons